

ASYMMETRIC SYNTHESIS OF (S,S,R)-(-)-ACTINONIN AND

ITS ANALOGS AND USES THEREFOR

BACKGROUND OF THE INVENTION

Cross-Reference to Related Applications

This non-provisional application claims benefit of
priority of provisional U.S. 60/277,116, filed March 19, 2001, now
abandoned.

Field of the Invention

The present invention relates generally to the fields of
organic chemistry and anti-tumor compounds. More specifically, the
present invention relates to the asymmetric synthesis of (S,R,R)-(-)-

actinonin and derivatives and analogs thereof and their uses as anti-tumor agents.

Description of the Related Art

5 (*S,S,R*)-(-)-Actinonin (1), was first isolated by Green and Singh from the Malayan strain of *Actinomycete*, *Streptomyces* sp. Cutter 12 (N.C.I.B. 8845) (Figure 1). It has been shown that actinonin exhibits antibiotic and anti-tumor properties (1-7). Studies have demonstrated that actinonin exhibits cytotoxicity towards
10 tumor cell lines *in vitro* (4). Furthermore, actinonin induces G₁ arrest and apoptosis in human leukemia and lymphoma cells. It also treats AKR leukemia in AKR mice with minimal toxicity.


 Although actinonin is commercially available and usually extracted from *Actinomycete* and *Streptomyces* bacteria, specifically
15 *Streptomyces roseopallidus* (9, 10), the yield of compound derived is miniscule. For example, out of a typical ten day culture that yields eleven liters of filtrate, only 146 mg of pure actinonin are isolated. Currently, actinonin is synthesized by either of two synthetic schema. In Ollis' 1975 synthetic method, the synthesis of actinonin
20 is non-stereoselective and the diastereomers have to be separated;

difficult process producing small yields (11). Davies' 1992 synthesis is stereoselective and represents the first asymmetric synthesis of (-)-actinonin. An Fe(II)-based chiral auxiliary is used to introduce chirality at the α -position of a carboxylic acid (13,14). However, this process causes disposal problems and therefore commercialization of the synthetic (-)-actinonin is doubtful. It is therefore necessary to develop a method for multi-gram synthesis of actinonin for further testing in various cancer cell lines and for animal studies.

The prior art is deficient in the lack of effective means of asymmetrically synthesizing (S,R,R)-(-)-actinonin, its derivatives and its analogs for use as anti-tumor agents. The present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

One embodiment of the present invention provides a chemical compound comprising an analog or a derivative of (S,S,R)-(-)-actinonin having the structure:



where R¹ is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine, where R¹ further comprises a cyclic or bicyclic structure; R² is methyl, CH₂CH₃, (CH₂)₂CH₃, C(CH₃)₃,
 5 phenyl, 3,4-dichlorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH₂-(N-Boc-4-piperidine), 4-tetrahydropyran, CH₂-4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl; R³ is R² or C₃₋₈alkyl, R⁴ is C₁₋₃alkyl; and R⁵ is NH₂, OH, NHOH, NHOCH₃, N(CH₃)OH, N(CH₃)OCH₃,
 10 NHCH₂CH₃, NH(CH₂CH₃), NHCH₂(2,4-(OCH₃)₂Ph, NHCH₂(4-NO₂)Ph, NHN(CH₃)₂, proline, or 2-hydroxymethyl pyrrolidine.

Another embodiment of the present invention provides a method for the treatment of a neoplastic disease comprising the step of administering to an individual in need of such treatment a
 15 pharmacologically effective dose of (S,S,R)-(-)-actinonin or other

((

chemical compound disclosed herein or a pharmaceutically acceptable salt or hydrate thereof.

Yet another embodiment of the present invention provides a method of inhibiting the growth of a tumor cell comprising the step of contacting said cell with a pharmacologically effective dose of (S,S,R)-(-)-actinonin or other chemical compound disclosed herein or a pharmaceutically acceptable salt or hydrate thereof.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention are briefly summarized

above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted; however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1A depicts the structure of (S,S,R)-(-)-actinonin (1).

Figure 1B depicts structurally how (S,S,R)-(-)-actinonin (1) is divided into fragments A, B and C

Figure 1C depicts the structure of Evan's chiral auxiliary (2).

Figure 2 depicts an alternative synthetic sequence for synthesizing and adding fragments A and C to fragment B for compounds having a benzyl functional group at R² (Scheme 1).

Figure 3A depicts the synthetic sequences for the α -pentylsuccinate fragment B (Scheme 2).

Figure 3B depicts the synthetic sequences for the pseudodipeptide derivative of L-prolinol and L-valine fragment A (Scheme 3)

Figure 3C depicts the synthetic sequences for the joining of fragments A, B and C to yield (S,S,R)-(-)-actinonin (Scheme 4).

Figure 4A shows the synthetic sequence of the actinonin analogs *N*4-hydroxy-*N*1-(1-(2-methyl-pyrrolidine-1-carbonyl)-3-methyl-propyl)-2-pentyl-succinamide (27) (Scheme 5).

Figure 4B shows the synthetic sequence of the actinonin analogs *N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl-succinamide (35) (Scheme 6).

10

DETAILED DESCRIPTION OF THE INVENTION

The following definitions are given for the purpose of facilitating understanding of the inventions disclosed herein. Any terms not specifically defined should be interpreted according to the common meaning of the term in the art.

As used herein, the term "alkyl" shall refer to optionally substituted straight, branched or cyclic hydrocarbon chains.

As used herein, the term “aryl” shall refer to optionally substituted aromatic mono- or bicyclic hydrocarbons.


As used herein, the term "individual" shall refer to animals and humans.

5 As used herein, the term "inhibiting" or "inhibition" of the growth of proliferating tumor cells shall include partial or total growth inhibition and also is meant to include decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose of the composition of the present invention may be determined
10 by assessing the effects of the test element on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell culture or any other method known to those of ordinary skill in the art.

The following abbreviations may be used herein:

15 THF: tetrahydrofuran; DMF: dimethylformamide; TFA: trifluoroacetic acid; n-BuLi: n-butyl lithium; OHsuccinNH: hydroxysuccinamide; HOBT: 1-hydroxybenzotriazole; EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DCC: dicyclohexylcarbodiimide; CH₂Cl₂: methylene chloride; and TLC: thin
20 layer chromatography.

One embodiment of the present invention provides a chemical compound comprising an analog or a derivative of (S,S,R)-(-)-actinonin having the structure:



5 where R^1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine, where R^1 further comprises a cyclic or bicyclic structure; R^2 is methyl, CH_2CH_3 , $(\text{CH}_2)_2\text{CH}_3$, $\text{C}(\text{CH}_3)_3$, phenyl, 3,4-dichlorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH_2 -(N-Boc-4-piperidine), 4-
 10 tetrahydropyran, CH_2 -4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl; R^3 is R^2 or C_{3-8} alkyl, R^4 is C_{1-3} alkyl; and R^5 is NH_2 , OH, NHOH , NHOCH_3 , $\text{N}(\text{CH}_3)\text{OH}$, $\text{N}(\text{CH}_3)\text{OCH}_3$, NHCH_2CH_3 , $\text{NH}(\text{CH}_2\text{CH}_3)$, $\text{NHCH}_2(2,4-(\text{OCH}_3)_2\text{Ph})$, $\text{NHCH}_2(4-\text{NO}_2)\text{Ph}$, $\text{NHN}(\text{CH}_3)_2$, proline, or 2-hydroxymethyl pyrrolidine.

15 In one aspect of this embodiment R^1 may be those functional groups disclosed in Table 1. Representative examples of

the compounds of the present invention are *N*4-hydroxy-*N*1-(1-(2-methyl-pyrrolidine-1-carbonyl)-3-methyl-propyl)-2-pentyl-succinamide (27), *N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl-succinamide (35), *N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl succinamide (41), *N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-*N*4-hydroxy-2-pentyl-succinamide (42), *N*4-hydroxy-*N*1-(1-(4-hydroxy-benzyl)-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide (43), *N*4-hydroxy-*N*1-(2-(2-hydroxymethyl-pyrrolidin-1-yl)-1(1*H*-indol-3-yl-methyl)-2-oxo-ethyl)-2-pentyl-succinamide (44), *N*1-(5-amino-1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-pentyl)-*N*4-hydroxy-2-pentyl-succinamide (45), *N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-piperidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (46), *N*4-hydroxy-*N*1-(1-(2-hydroxycarbamoyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl succinamide (47), *N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-methyl-succinamide (48), *N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl-succinamide (49), and *N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide

(5 0), *N*1-(1-(2-methyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (5 1), *N*4-hydroxy-*N*1-(1-benzyl-2-(2-methyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (5 2), *N*4-hydroxy-*N*1-(1-(2-methylamine-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (5 3), 3-[1-(2-hydroxymethyl-pyrrolidin-1-yl)-2-benzylcarbamoyl]-octanoic acid (5 4) , *N*4-hydroxy-*N*1-(1-(methyl-2-carboxy-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (5 5), *N*4-hydroxy-*N*1-(1-(2-carboxy-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (5 6), *N*4, *N*4-diethyl -*N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (5 7), *N*4-ethyl-*N*1-(1-benzyl-2-(2-hydroxymethyl -pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (5 8), *N*4-(2,4-methoxybenzyl)-*N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (5 9), 2-(*N*',*N*'-dimethyl-hydrazinocarbonylmethyl)-heptanoic acid [1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-amide (6 0), *N*4-(4-nitrobenzyl)-*N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (6 1), 2-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-heptanoic acid [1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-amide (6 2), *N*4-

(methoxy)-*N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (63), *N*4-(piperidin -1-carbonyl)-*N*1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (64), or *N*4, *N*4-methoxymethyl-*N*1-(1-benzyl-2-(2-hydroxymethyl- pyrrolidin-1-yl)-2-oxo-ethyl-2-pentyl- succinamide (65). Pharmaceutical compositions of these compounds are also provided.

In another aspect of this embodiment there is provided a general method of synthesis of (S,S,R)-(-)-actinonin and its analogs and derivatives. This method comprises the steps of forming an optionally *O*-protected R^1 -1-carbonyl-C2-(R^2)-methYLENEamine from R^1 and an *N*-protected R^2 -amino acid 2,5-dioxo-pyrrolidinyl ester and deprotecting said *N*-protected R^2 -amino acid with a suitable agent comprising trifluoroacetic acid; forming an R^3 -carbonyl-oxazolidone from 4-isopropyl-oxazolidin-2-one and R^3 -carbonyl chloride; treating a solution of 4-(*S*)-isopropyl-oxazolidin-2-one with a solution of a base comprising *n*-butyl lithium in hexanes and adding an R^3 -carbonyl chloride thereby forming an R^3 -carbonyl oxazolidinone; treating a solution of the R^3 -carbonyl oxazolidinone sequentially with a base comprising lithium diisopropylamide and with a bromo-

R^4 acid-*tert*-butyl ester thereby forming an oxazolidine- R^3 -carbonyl- R^4 -acid *tert*-butyl ester; treating a mixture of the an oxazolidine- R^3 -carbonyl- R^4 -acid *tert*-butyl ester in tetrahydrofuran and water sequentially with hydrogen peroxide in water and with lithium
5 hydroxide in water thereby forming a $C2(R^3)$ - R^4 -dicarboxylic acid *tert*-butyl ester; treating a mixture of the $C2(R^3)$ - R^4 -dicarboxylic acid 4-*tert*-butyl ester and hydroxysuccinimide in a solvent comprising dioxane or dimethylformamide with an imide comprising dicyclohexylcarbodiimide thereby forming an $C2(R^3)$ - R^4 -dicarboxylic
10 acid *tert*-butyl ester-(2,5-dioxo-pyrrolidin-1-yl) ester; treating a solution of the optionally *O*-protected R^1 -1-carbonyl- $2C(R^2)$ -methyleneamine in a solvent comprising tetrahydrofuran sequentially with triethylamine and with the $C2(R^3)$ - R^4 -dicarboxylic acid *tert*-butyl ester-(2,5-dioxo-pyrrolidin-1-yl) ester thereby
15 forming an optionally *O*-protected R^1 -1-carbonyl- $C2(R^2)$ -carbamoyl-methylene(R^3)- R^4 -carboxylic acid *tert*-butyl ester; treating a solution of said optionally *O*-protected R^1 -1-carbonyl- $C2(R^2)$ -carbamoyl-methylene(R^3)- R^4 -carboxylic acid *tert*-butyl ester in a solvent comprising methylene chloride with trifluoroacetic acid thereby
20 forming an optionally *O*-protected R^1 -1-carbonyl- $C2(R^2)$ -carbamoyl-

()

methylene(R³)-R⁴-carboxylic acid; treating the optionally *O*-protected R¹-1-carbonyl-C2- (R²)-carbamoyl-methylene(R³)-R⁴-carboxylic acid and hydroxysuccinamide with an imide comprising dicyclohexylcarbodiimide thereby forming a optionally *O*-protected

5 R¹-1-carbonyl-C2(R²)-carbamoyl-methylene(R³)-R⁴-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester; treating a suspension of R⁵ or the chloride thereof, where R⁵ is optionally *O*-protected, in a solvent comprising dimethylformamide sequentially with triethylamine and with a solution of the *O*-protected R¹-1-carbonyl-C2(R²)-carbamoyl-

10 methylene(R³)-R⁴-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester in a solvent comprising dimethylformamide thereby forming an R¹-1-carbonyl-C2(R²)- carbamoyl-methylene(R³)-R⁴-carbonyl-R⁵, where R¹ and R⁵ are independently optionally *O*-protected; and hydrogenating R¹ and R⁵, where R¹ and R⁵ independently comprise an *O*-protecting

15 group, with hydrogen gas and a catalyst comprising palladium hydroxide in activated carbon where (S,S,R)-(-)-actinonin or a chemical compound disclosed herein is formed.

In an aspect of this embodiment when the R¹-R⁵ substituents are such R¹ is 2-hydroxymethyl-pyrrolidine; R² is benzyl;

20 R³ is pentyl; R⁴ is methylene; and R⁵ is NHOCH₃, N(CH₃)OCH₃,

((

NHCH₂CH₃, NH(CH₂CH₃)₂, NHCH₂(2,4-(OCH₃)₂Ph, NHCH₂(4-NO₂)Ph, NHN(CH₃)₂, piperidine or 1-methyl-piperazine an alternate method of synthesis may be used. L-phenylalanine, 2-hydroxymethyl pyrrolidine and R⁵ are sequentially coupled to 2-pentylsuccinic acid
5 4-*tert*-butyl ester 4-(2,5-dioxo-pyrrolidin-1-yl) ester by the method disclosed *infra*.

In yet another aspect of this embodiment the R¹- R⁵ substituents are such that R¹ is 2-hydroxymethyl-pyrrolidine, 2-methylpyrrolidine, 2-methylamine-pyrrolidine, methyl-2-pyrrolidine
10 carboxylate, or 2-hydroxycarbamoyl; R² is methyl, benzyl, 4-hydroxybenzyl, methylethyl, 2-methyl propyl, 3-methyl-indolyl; R³ is methyl or pentyl; R⁴ is methylene; and R⁵ is NH₂, OH, NHOH, NHOCH₃, N(CH₃)OH, N(CH₃)OCH₃, NHCH₂CH₃, NH(CH₂CH₃), NHCH₂(2,4-(OCH₃)₂Ph, NHCH₂(4-NO₂)Ph, NHN(CH₃)₂, proline, 2-hydroxymethyl
15 pyrrolidine. piperidine or 1-methyl-piperazine.

In yet another aspect of this embodiment the R¹- R⁵ substituents are such that R¹ is 2-methyl pyrrolidine, 2-hydroxymethyl pyrrolidine or 2- hydroxycarbamoyl pyrrolidine; R² is methyl, CH₂CH₃, (CH₂)₂CH₃, C(CH₃)₃; R³ is R² or C₄₋₇alkyleneCH₃, R⁴

((

is methylene; and R⁵ is hydroxyamine. The specific synthetic method for this particular aspect is as disclosed *infra*.

In yet another aspect of this embodiment the R¹- R⁵ substituents are such that R¹ is 2-hydroxymethyl pyrrolidine; R² is methylethyl; R³ is pentyl; R⁴ is methylene; and R⁵ is hydroxyamine. (S,S,R)-(-)-actinonin is synthesized in this aspect using the specific method disclosed *infra*.

The compounds and methods of the present invention may be used to treat neoplastic diseases. Another embodiment of the present invention provides a method for the treatment of a neoplastic disease comprising the step of administering to an individual in need of such treatment a pharmacologically effective dose of (S,S,R)-(-)-actinonin or other chemical compound disclosed herein or a pharmaceutically acceptable salt or hydrate thereof.

Representative examples of preferred compounds used for treatment are N4-hydroxy-N1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl-succinamide **35**, N1-(1-(2-methyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (**52**), N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-N4-hydroxy-2-pentyl-succinamide (**42**), N4-hydroxy-


((

*N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-
2-methyl-succinamide (4 8), *N*4-hydroxy-*N*1-(1-benzyl-2-(2-methyl-
pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (5 3) or *N*4-
hydroxy-*N*1-(1-(methyl-2-carboxy-pyrrolidine-1-carbonyl)-2-methyl-
5 propyl)-2-pentyl-succinamide (5 6).

Treatment is specifically contemplated in a human.
Representative examples of neoplastic diseases include, but are not
limited to, human ovarian carcinoma, prostate carcinoma, mammary
carcinoma, head and neck squamous cell carcinoma (HNSSC), non-
10 small-cell-lung-cancer adenocarcinoma (NSCLC-AdCa), non-small-
cell-lung-cancer squamous cells (NSCLC-SSC), and acute myelogenous
leukemia (AML) cells.

Yet another embodiment of the present invention
provides a method of inhibiting the growth of a tumor cell
15 comprising the step of contacting said cell with a pharmacologically
effective dose of (S,S,R)-(-)-actinonin or other chemical compound
disclosed herein or a pharmaceutically acceptable salt or hydrate
thereof. Again representative examples of these compounds and
tumor types are those as disclosed *supra*.

Thus the present invention is directed toward the synthesis and characterization of novel agents that inhibit tumor growth *in vitro* and *in vivo*. More specifically, this invention provides for the asymmetric synthesis and effective use of (S,S,R)-(-)-
 5 actinonin (1) and its derivatives and analogs as inhibitors of tumor growth in neoplastic diseases. The novel (S,S,R)-actinonin analogs and derivatives of the present invention have the general formula shown below:



10 Generally, the compounds are substituted succinamides with R⁴ as a methylene group although dicarboxylic acids where R⁴ is either ethylene or propylene may be synthesized. The amide functional group R⁵ may be mono- or di-substituted with a C₁₋₂ -alkyl, -alkoxy or phenoxy group(s), preferably R⁵ is hydroxyamine. R² and
 15 R³ are primarily alkyl although these sidechains may be heterocycles,

e.g., piperidinyl, naphthyl, pyridyl, or thienyl. Preferably R^2 is a branched C_{2-3} alkyl and R^3 is pentyl.

In the present invention R^1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine and usually
5 comprises a cyclic or bicyclic structure. R^1 may be a mono- or di-substituted simple straight chain or cyclic amine such as methyl, ethyl or benzyl amine or optionally substituted proline, azetidine, aziradine, or hexa- or heptamethyleneamine. Generally R^1 is a heterocycle optionally substituted in the C2 or C3 positions on the
10 ring. Preferably the heterocycle is pyrrolidine, but may also be pyrrole, indole, indoline, morpholine, piperidine, isoquinoline, or piperazine. Ring substitutions at the C2 or C3 positions can be methyl, ethyl, benzyl, or the heterocyclic esters thereof with hydroxymethyl, methyl or hydroxycarbamoyl the preferred
15 substituent on the pyrrolidine ring. Additionally the heterocycles may be substituted with other heterocycles such as pyridinyl, isonicotinyl or furfuryl rings. The heterocycles may be halogenated on any of the available ring positions with a representative example being the fluoroindolines. The substituents disclosed for these R^1 - R^5
20 groups are not limited to these groups and are not in any way

limiting to the scope of the invention. Table I details the R¹ group substituents for these actinonin analogs.

TABLE 1

5

R¹ substituents for analogs/derivatives of (S,S,R)-(-)-actinonin

Compound substituents

			ester	
10	<u>Compound</u>	<u>alkyl/aryl</u>	<u>(carboxylate)</u>	<u>Misc.</u>
	pyrrole			
	indole			
	aziradine			
	imidazole			
15	proline		methy ethyl t-butyl	
20	azetidine	2 or 3-methyl 2 or 3-ethyl	2 or 3-methyl 2 or 3-ethyl 2 or 3-t-butyl	
	indoline		methyl-2	2-7 Fl
25	pyrrolidine	2 or 3-methyl 2 or 3-ethyl 2 or 3-t-butyl 2 or 3-phenyl	methyl-2 ethyl-2 t-butyl-2 benzyl-2	2-NHCH ₃ 2 or 3-NHOH 2-OHcarbamoyl
30		2,3-dimethyl 2,4-dimethyl 2,5-dimethyl 2,5-diethyl	methyl-2-methyl-5	

	piperidine	2 or 3-methyl 2 or 3-ethyl	methyl-2, -3 or -4 ethyl-2, -3 or -4 benzyl-2, -3 or -4
5	morpholine		methyl-2 or -3 ethyl-2 or -3 benzyl-2 or -3
10	piperazine	1-benzyl	1-furfuryl 1-isonicotinoyl N-tBoc pyridin-2-yl-methyl pyridin-3-yl-methyl pyridin-4-yl-methyl
15	hexamethyleneamine		methyl-2 or -3
	heptamethyleneamine		
20	NH(R) or NRR	methyl ethyl benzyl dimethyl diethyl	
25		2,4-dimethoxy 4-nitrobenzyl	benzyl
30	1,4-dioxan-2-yl- methylaniline		
	3,4-dihydro-2H- 1,4-benzoxazin-6-ol		
35	6-methoxy-1,2,3,4- tetrahydro-isoquinoline		
	piperazin-1-yl-pyridin- 3-yl-methanone		

((





It should be clear that corresponding actinonin analogs or derivatives readily can be formed using the synthetic methods as provided for (S,S,R)-(-)-actinonin (**1**) (Figure 1A) and the analogs or derivatives disclosed herein. The synthetic schema detailed herein
5 provide a scalable process for the asymmetric synthesis of (S,R,R)-(-)-actinonin and its analogs and derivatives. The general structure of these compounds can be divided into three fragments. Fragment A is described as a pseudodipeptide. Fragment B is a succinnic acid or other dicarboxylic acid derivative and is composed of a dicarboxylic
10 acid skeleton functionalized with an R³ group at C2 (or at C3 or C4, depending on the acid) or, alternatively, the α - (or β - or γ -) R³ ester. Fragment C is an optionally suitably protected optionally substituted amine. Figure 1B depicts these fragments for actinonin.

A generalized synthetic scheme to synthesize any of the
15 compounds disclosed herein is shown below. The (-)-actinonin analogs and derivatives are prepared by substituting various amino acids and other reagents to the process. Some substituents would need to be O- or N-protected, e.g., hydroxyl functions on R¹ and R⁵ or the amine in the R²-amino acid in Fragment A. Fragment B may not
20 be commercially available and would have to be synthesized

independently. This involves the use of an Evan's chiral auxiliary 2 (13) (Figure 1C). This chiral auxiliary route provides an easily prepared and inexpensive alternative to the iron (Fe)-based chiral auxiliary. It is contemplated that other structures may be synthesized using the methods disclosed herein.

Fragment A:

a) An optionally *O*-protected R^1 -1-carbonyl-C2-(R^2)-methyleneamine from R^1 and an *N*-protected R^2 -amino acid 2,5-dioxo-pyrrolidinyl ester is formed. A suitable agent, e.g. trifluoroacetic acid (TFA) deprotects the *N*-protected R^2 -amino.



Fragment B:

b) Forming an R^3 -carbonyl-oxazolidone from 4-isopropyl-oxazolidin-2-one and R^3 -carbonyl chloride;

((



c) Treating a solution of 4-(*S*)-isopropyl-oxazolidin-2-one with a solution of a base, e.g., *n*-butyl lithium in hexanes, and adding an R³-carbonyl chloride to form an R³-carbonyl oxazolidinone.

5 d) Treating a solution of the R³-carbonyl oxazolidinone sequentially with a base, e.g., lithium diisopropylamide, and with a bromo-R⁴ acid-*tert*-butyl ester to form an oxazolidine-R³-carbonyl-R⁴-acid-*tert*-butyl ester.


e) Treating a mixture of the an oxazolidine-R³-
10 carbonyl-R⁴-acid *tert*-butyl ester in tetrahydrofuran and water sequentially with hydrogen peroxide in water and with lithium hydroxide in water to form a C2(R³)-R⁴-dicarboxylic acid *tert*-butyl ester;

f) Treating a mixture of the C2(R³)-R⁴-dicarboxylic
15 acid 4-*tert*-butyl ester and hydroxysuccinimide in a solvent, e.g., dioxane or dimethylformamide, with an imide, e.g., dicyclohexylcarbodiimide to form an C2(R³)-R⁴-dicarboxylic acid *tert*-butyl ester-(2,5-dioxo-pyrrolidin-1-yl) ester.

20 Cl-CO-R³ + 4-isopropyl-oxazolidin-2-one → R³-CO-oxazolidone



5





Fragment A + Fragment B:

10 g) Treating a solution of the optionally *O*-protected R¹-
1-carbonyl-2-(R²)-methyleamine in a solvent, e.g., tetrahydrofuran,
sequentially with triethylamine and with the C2(R³)-R⁴-dicarboxylic
acid *tert*-butyl ester-(2,5-dioxo-pyrrolidin-1-yl) ester to form an
optionally *O*-protected R¹-1-carbonyl-2-(R²)-carbamoyl-
15 methylene(R³)-R⁴-carboxylic acid *tert*-butyl ester.

h) Treating a solution of the optionally *O*-protected R¹-
1-carbonyl-C2(R²)-carbamoyl-methylene(R³)-R⁴-carboxylic acid *tert*-
butyl ester in a solvent, e.g., methylene chloride, with TFA to form an
optionally *O*-protected R¹-1-carbonyl-C2(R²)-carbamoyl-
20 methylene(R³)-R⁴-carboxylic acid.

i) Treating the optionally *O*-protected R¹-1-carbonyl-
2C- (R²)-carbamoyl-methylene(R³)-R⁴- carboxylic acid and

hydroxysuccinamide with an imide, e.g., DCC, to form an optionally *O*-protected R¹-1-carbonyl-C2(R²)- carbamoyl-methylene(R³)-R⁴-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester.




Fragment C + Fragment A-B:

j) Treating a suspension of an optionally *O*-protected R⁵ or its chloride in a solvent, e.g., DMF, sequentially with
 15 triethylamine and with a solution of the *O*-protected R¹-1-carbonyl-C2(R²)-carbamoyl-methylene(R³)-R⁴-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester in a solvent, e.g., DMF, to form an R¹-1-carbonyl-C2(R²)- carbamoyl-methylene(R³)-R⁴-carbonyl-R⁵ where R¹ and R⁵ may be independently *O*-protected.

20 k) Hydrogenating R¹ and R⁵, if R¹ and R⁵ independently have an *O*-protecting group, with hydrogen gas and a



ester to form an 3-(1-Carboxy-2-phenyl-ethylcarbamoyl)-octanoic acid tert-butyl ester.



Adding R¹ or 2-hydroxymethyl pyrrolidine:

b) Coupling 2-hydroxymethyl pyrrolidine to 3-(1-Carboxy-2-phenyl-ethylcarbamoyl)-octanoic acid tert-butyl ester in a
10 solvent, e.g., methylene chloride, and in the presence of EDC and HOBT to form 3-[1-(2-hydroxymethyl-pyrrolidin-1-yl)-2-benzylcarbamoyl]-octanoic acid 4-*tert*-butyl ester.

c) Treating a solution of 3-[1-(2-hydroxymethyl-pyrrolidin-1-yl)-2-benzylcarbamoyl]-octanoic acid 4-*tert*-butyl ester
15 in a solvent, e.g., methylene chloride, with TFA to form 3-[1-(2-hydroxymethyl-pyrrolidin-1-yl)-2-benzylcarbamoyl]-octanoic acid.



Adding R⁵:

d) Treating a suspension of R⁵ in a solvent, e.g., methylene chloride, and in the presence of EDC and HOBT with a solution of 3-[1-(2-hydroxymethyl-pyrrolidin-1-yl)-2-benzyl carbamoyl]-octanoic acid in methylene chloride to form N4(R⁵)-N1-[1-benzyl-2(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-2-pentyl-succinamide.



10 →



It is also contemplated that these analogs are to be used as anti-tumor agents or for the use in the treatment of neoplastic diseases by the methods disclosed herein. It is specifically contemplated that pharmaceutical compositions may be prepared using the novel actinonin analogs of the present invention. In such a case, the pharmaceutical composition comprises the novel compounds of the present invention and a pharmaceutically acceptable carrier. When used *in vivo* for therapy, the compounds of

15
20

the present invention are administered to the patient or an animal in therapeutically effective amounts, i.e., amounts that eliminate or reduce the tumor burden. A person having ordinary skill in this art would readily be able to determine, without undue experimentation, the appropriate dosages and routes of administration of the compounds and derivatives of the present invention.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1

General Methods and Materials

The ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker 400 MHz using tetramethylsilane as the internal standard. High resolution mass spectra were obtained at the Mass Spectrometry Facility, University of California at Riverside. All reagents are obtained either from Sigma-Aldrich® or from Lancaster® and vacuum dried under P_2O_5 overnight before use. All solvents

were reagent grade and distilled before use. Silica gel used for chromatography, MN-Kieselgel 60, was purchased from Brinkman Instruments Inc. All reactions were carried out under argon using glassware dried in an oven at 80 °C overnight and cooled under vacuum. The reaction mixtures were mechanically stirred using a magnetic stirring bar and stirring plate. Melting points were determined using a Mel-Temp II melting point apparatus fitted with a digital Barnart 115 thermocouple thermometer, and are uncorrected.

10

EXAMPLE 2

General synthetic protocol for actinonin and specific analogs

For actinonin and those analogs or derivatives where R¹ is 2-methyl pyrrolidine, 2-hydroxymethyl pyrrolidine or 2-hydroxycarbamoyl pyrrolidine; and R² is methyl, CH₂CH₃, (CH₂)₂CH₃, C(CH₃)₃ and R³ is R² or C₄₋₇alkyleneCH₃, the following protocol can be used:

a) Coupling of a suitably O - protected methoxypyrrolidine or a derivative thereof with a suitably N -

protected amino acid 2,5-dioxo-pyrrolidinyl ester to form suitable *N,O*-protected methylpyrrolidine-1-carbonyl-2-methylamine.

b) Deprotection of the *N*protecting group with a suitable deprotecting agent such as trifluoroacetic acid to yield the
5 corresponding pyrrolidine-1-carbonyl-2-methylamine or a derivative thereof.

c) Treatment of a solution of a chiral auxiliary, such as 4-(*S*)-isopropyl-oxazolidin-2-one **2**, with a solution of a suitable base, such as *n*-BuLi in hexanes, followed by the addition of an alkynoyl
10 chloride to yield an alkynoyloxazolidinone.

d) Treatment of a solution of the alkynoyloxazolidinone with lithium diisopropylamide, or similar bases, followed by bromoacetic acid *tert*-butyl ester to yield an oxazolidine-carbonyl-alkynoic acid *tert*-butyl ester.

15 e) Treatment of a mixture of an oxazolidine-carbonyl-alkynoic acid *tert*-butyl ester in THF/water with hydrogen peroxide in water followed by lithium hydroxide in water to yield an alkylsuccinic acid 4-*tert*-butyl ester.

f) Treatment of a mixture of an alkylsuccinic acid 4-
20 *tert*-butyl ester and hydroxysuccinimide **7** in a suitable solvent,

such as dioxane or dimethylformamide, with dicyclohexylcarbodiimide, or similar imides, to afford an alkylsuccinic acid 4-*tert*-butyl ester 4-(2,5-dioxo-pyrrolidin-1-yl) ester.

5 g) Treatment of a solution of a pyrrolidine-1-carbonyl-2-methylamine or a derivative thereof in a suitable solvent is treated with triethylamine followed by an alkylsuccinic acid 4-*tert*-butyl ester 4-(2,5-dioxo-pyrrolidin-1-yl) ester to yield a pyrrolidine-1-carbonyl-2-methylalkyl-carbamoyl-alkynoic acid *tert*-butyl ester or a
10 derivative thereof.

 h) Treatment of a pyrrolidine-1-carbonyl-2-methylalkyl-carbamoyl-alkynoic acid *tert*-butyl ester or a derivative thereof in a suitable solvent with trifluoroacetic acid to yield a pyrrolidine-1-carbonyl-2-methyl-alkylcarbamoyl-alkynoic acid or a
15 derivative thereof.

 i) Treatment of a pyrrolidine-1-carbonyl-2-methyl-alkylcarbamoyl-alkynoic acid or a derivative thereof and hydroxysuccinamide (7) with dicyclohexylcarbodiimide or any suitable imide to afford a pyrrolidine-1-carbonyl-2-

((

methylalkylcarbamoyl)-alkynoic acid 2,5-dioxo-pyrrolidin-1-yl ester or a derivative thereof.

j) Treatment of a suspension of *O*-benzylhydroxyamine hydrochloride **18** in a suitable solvent with
5 triethylamine followed by a solution of a pyrrolidine-1-carbonyl-2-methylalkylcarbamoyl)-alkynoic acid 2,5-dioxo-pyrrolidin-1-yl ester or a derivative thereof in a suitable solvent to afford *N*4-benzyloxy-*N*1-(1-(pyrrolidine-1-carbonyl)-2-methylalkyl-2-alkyl-succinamide or a derivative thereof.

10 k) Hydrogenation of a *N*-benzyloxy-*N*1-(1-(pyrrolidine-1-carbonyl)-2-methylalkyl-2-alkyl-succinamide or a derivative thereof with hydrogen gas and a suitable catalyst wherein actinonin or its analogs are thereby formed.

15

EXAMPLE 3

Specific synthesis of (S,R,R)-(-)-actinonin

(S,R,R)-(-)-Actinonin is divided into three fragments A, B
20 and C as previously disclosed. Fragment A, described as a

pseudodipeptide, is composed of a (*S*)-prolinol and a (*S*)-valine. Fragment **B**, described as a succinnic acid derivative, is composed of a succinnic acid skeleton functionalized with an *n*-pentyl group at C2 or, alternatively, an α -pentylsuccinate. Fragment **C** is a suitably
5 protected hydroxylamine (Figure 1B).

Synthesis of Fragment A

Fragment **A** is prepared by coupling a suitably *N*-protected and carboxy-activated (*S*)-valine and a suitably *O*-
10 protected (*S*)-prolinol. The α -pentylsuccinate fragment **B** is synthesized using an Evan's chiral auxiliary **2** (13) (Figure 1C).

Synthesis of Fragment B

The synthesis of Fragment **B** is comprised of the following
15 steps: (a) a solution of 4-(*S*)-isopropyl-oxazolidin-2-one **2** in THF at a temperature of -78 °C is treated with a solution of *n*-BuLi in hexanes, or any suitable base; (b) heptanoyl chloride **3** is added to the mixture to yield 3-heptanoyl-4-(*S*)-isopropyl-oxazolidin-2-one **4**; (c) treatment of a solution of **4** in THF with lithium diisopropylamide, or
20 similar bases, followed by bromoacetic acid *tert*-butyl ester yield 3-

(
(
(4-(*S*)-isopropyl-2-oxo-oxazolidine-3-(*S*)-carbonyl)octanoic acid *tert*-butyl ester **5**; (d) treatment of a mixture of **5** in THF/water with hydrogen peroxide in water followed by lithium hydroxide in water at 0 °C to yield 2-(*R*)-pentylsuccinic acid 4-*tert*-butyl ester **6**; (e)
5 treatment of a mixture of **6** and hydroxysuccinimide **7** in dimethylformamide or any suitable solvent, such as dioxane, with dicyclohexylcarbodiimide, or similar imides, to afford 2-(*R*)-pentylsuccinic acid 4-*tert*-butyl ester (should this be 1, if it is 4-*t*-butyl ester?)4-(2,5-dioxo-pyrrolidin-1-yl) ester **8** (Scheme 2, Figure
10 3A).

Synthesis of fragment A

The synthesis is comprised of the following steps: (a) a solution of 2-(*S*)-benzyloxymethylpyrrolidine **10** in THF is treated
15 with triethylamine followed by a solution of 2-*tert*-butoxycarbonylamino-3-methylbutyric acid 2,5-dioxo-pyrrolidin-1-yl
12 in THF to yield (1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-carbamic acid *tert*-butyl ester **13**; which is then (b)
dissolved in methylene chloride, or any suitable solvent, and treated
20 with trifluoroacetic acid or any suitable Boc-deprotecting agent to

yield 2-amino-1-(2-benzyloxymethylpyrrolidin-1-yl)-3-methylbutan-1-one **14** (Scheme 3, Figure 3B).

A problem can occur with overhydrogenation involving the hydroxylamine group being converted to the corresponding amide. However, this could be avoided by carefully monitoring the amount of hydrogen consumed during hydrogenation. In some occasions, when the overreduction product is observed in TLC, the reaction is quenched, the product is isolated, and the starting material resubjected to hydrogenation.

Synthesis of (-)-actinonin using fragments A, B and C

The coupling of fragment A and B is comprised of the following steps: (a) a solution of **14** in dimethylformide or any suitable solvent is treated with triethylamine followed by a solution of **8** in dimethylformamide or any suitable solvent to yield 3-(1-(2-(*S*)-benzyloxymethylpyrrolidine-1-carbonyl)-2-(*S*)-methylpropyl-carbamoyl)-octanoic acid *tert*-butyl ester **15**; (b) treatment of **15** in dichloromethane with trifluoroacetic acid to yield 3-(1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl-carbamoyl)-octanoic acid **16**; (c) treatment of a solution **16** and

((

hydroxysuccinamide **7** with dicyclohexylcarbodiimide or any suitable imide to afford 3-(1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methylpropylcarbamoyl)-octanoic acid 2,5-dioxo-pyrrolidin-1-yl ester **17**; (d) fragment **C** is introduced by treatment of a suspension of *O*-benzylhydroxyamine hydrochloride **18** in dimethylformamide with triethylamine followed by a solution of **17** in dimethylformamide to afford *N*4-benzyloxy-*N*1-(1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide **19**. (f) hydrogenating **19** with hydrogen gas and palladium hydroxide in activated carbon wherein actinonin **1** is thereby formed (Scheme 4, Figure 3C).

15

EXAMPLE 4

Synthesis of Specific Compounds in Schemes 1, 2 and 3

Synthesis of 3-heptanoyl-4-(*S*)-isopropyl-oxazolidin-2-one (**4**)

To a solution of oxazolidone (**2**) (30.2 g, 0.234 mol) in 400 mL THF at -78 °C was added *n*-BuLi (2.5 M in hexanes, 96.0 mL,

()

0.240 mol) dropwise over a period of 30 min. The solution was stirred at -78°C for an hour. Heptanoyl chloride (37.15 g, 0.250 mol) was gradually added by syringe and the resulting solution stirred at -78°C for 1 h and then warmed to 0°C . A saturated aqueous solution of NH_4Cl (100 mL) was added and the mixture gradually warmed to room temperature. The mixture was extracted with ethyl acetate (3 x 20 mL) and the combined organic layers were washed with brine and dried over anhydrous MgSO_4 . The solvent was removed by a rotary evaporation and the yellowish residue chromatographed on a silica gel column using Hexane/EtOAc (8:1) as the eluant to give **4** as a colorless oil (46.272 g, 0.192 mol, 82 %).

^1H NMR (400 MHz, CDCl_3) δ 0.87 (t, $J=7.2$ Hz, 3 H), 0.88 (d, $J=16.9$ Hz, 3 H), 0.90 (d, $J=16.9$ Hz, 3 H), 1.24-1.39 (m, 6 H), 1.59-1.69 (m, 2 H), 2.31-2.43 (m, 1 H), 2.81-3.02 (m, 2 H), 4.19-4.29 (m, 2 H), 4.41-4.45 (m, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.9, 14.5, 17.9, 22.4, 24.3, 28.3, 28.7, 31.4, 35.4, 58.3, 63.2, 154.0, 173.4.

((

Synthesis of 3-(S)-(4-(S)-isopropyl-2-oxo-oxazolidine-3-carbonyl)-octanoic acid *tert*-butyl ester (5)

To a solution of **4** (37.082 g, 0.154 mol) in THF (300 mL) at -78 °C is added LiHMDS in THF (1.0 M, 0.162 mol, 162 mL) via
5 cannula. The solution is stirred at -78 °C for 1 h. *tert*-Butylbromoacetate is added and then stirred for 30 more minutes. It is then gradually warmed to 0 °C and stirred at this temperature for 30 min. To this solution is gradually added 100 mL saturated aqueous solution of NH₄Cl. The bulk of the THF is removed by rotary
10 evaporation and the remaining mixture was extracted with CH₂Cl₂ (100 mL x 3). The combined CH₂Cl₂ extracts is washed consecutively with 1N NaOH, 1 N HCl, saturated NaHCO₃, and brine. It is then dried over MgSO₄ and concentrated *in vacuo*. The residue is chromatographed in silica gel using hexane/ethyl acetate (5:1) as
15 eluant to afford **5**. ¹H NMR (400 MHz, CDCl₃) δ 0.85 (t, J= 6.8 Hz, 3 H), 0.91 (d, J= 8.15 Hz, 3 H), 0.93 (d, J= 8.15 Hz, 3 H), 1.18-1.35 (m, 6 H), 1.40 (s, 9 H), 1.35-1.49 (m, 1 H), 1.56-1.66 (m, 1 H), 2.31-2.39 (m, 1 H), 2.44 (dd, J= 16.6, 4.5, 1 H), 2.73 (dd, J= 16.6, 10.3, 1 H), 4.11-4.20 (m, 1 H), 4.44 (m, 1 H); ¹³C NMR (75.45 MHz, CDCl₃) δ

((

13.9, 14.4, 17.9, 22.4, 26.4, 27.9, 28.0, 31.4, 31.6, 31.7, 37.0, 39.2, 58.6, 62.9, 80.3, 153.5, 171.2, 175.8. HRMS calcd for $C_{19}H_{34}NO_5$ (MH^+): 356.2436. Found (DCI): 356.2418 ($\Delta = 5.3$ ppm).

5 Synthesis of 2-(*R*)-pentylsuccinic acid 4-*tert*-butyl ester (6)

A solution of **5** (25.5 g, 71.73 mmol) in THF (300 mL) and water (75 mL) under Ar is cooled to 0 °C. To this is added via syringe H_2O_2 (30 % in water, 30.6 mL, 0.300 mol) gradually over a period of 15 minutes. $LiOH \cdot H_2O$ (4.92 g, 0.12 mol) in water (150 mL) is added via syringe. The mixture is stirred for 3 h after which the septum is removed and Na_2SO_3 (37.8 g, 0.300 mol) in water (225 mL) is added slowly. The bulk of the THF is removed by rotavap at a bath temperature between 25 – 30 °C. The residue is extracted with CH_2Cl_2 (100 mL x 3). The combined organic layer is washed consecutively with 0.5 N HCl (100 mL), sat. $NaHCO_3$ (100 mL), water (100 mL) and brine (100 mL). The solution is then dried over Na_2SO_4 and concentrated *in vacuo*. The residue is recrystallized in hexane/ethyl acetate to afford the Evan's chiral auxiliary **2** as white needles. The aqueous layer from the first extraction was acidified to pH 1 and extracted with ethyl acetate (100 mL x 3). The combined

organic layer is washed with 0.5 N HCl (100 mL) and then brine (100 mL). It is then dried over Na₂SO₄ and concentrated to yield **6** as a colorless oil (17.198 g, 70.39 mmol, 98 %). ¹H NMR (400 MHz, CDCl₃) δ 0.88 (t, J= 6.8 Hz, 3 H), 1.21-1.37 (m, 6 H), 1.43 (s, 9 H), 1.40-1.70 (m, 2 H), 2.61 (dd, J= 9.3 Hz, 1 H), 2.38 (dd, J= 16.4, 5.1, 1 H), 2.61 (dd, J= 16.4, 9.3, 1 H), 2.78 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 17.5, 17.9, 22.3, 26.5, 27.9, 31.5, 37.0, 41.3, 94.9, 80.0, 171.1, 181.1. HRMS calcd for C₁₃H₂₅O₄ (MH⁺): 245.1752. Found (DCI): 245.1766 (Δ= 5.2 ppm).

10

Synthesis of 2-(*R*)-pentyl-succinic acid 4-*tert*-butyl ester 4-(2,5-dioxo-pyrrolidin-1-yl) ester (**8**)

To a solution of **6** (7.149 g, 29.26 mmol) and *N*-hydroxysuccinimide (6.90 g, 60.0 mmol) in 1,4-dioxane (40 mL) at r.t. is added via cannula a solution of DCC (8.25 g, 40 mmol) in 1,4-dioxane (20 mL). The mixture is stirred overnight, afterwhich it is filtered through celite and the solids washed with acetone. The filtrate is concentrated *in vacuo* and the residue redissolved in acetone. The acetone solution is cooled to 0 °C and filtered again.

under vacuum. The yellowish oil is dissolved in THF (100 mL), cooled to 0 °C, and treated with NaH (6.0 g, 0.250 mol). Benzyl bromide (34.2 g, 0.20 mol) is added dropwise. The mixture is stirred overnight after which it is cooled to 0 °C and a saturated solution of NH₄Cl is added slowly. The layers are separated and the THF layer is diluted with ethyl acetate (50 mL). This solution is washed with 1 N HCl (50 mL) and then brine (50 mL). The solution is then concentrated *in vacuo*. The residue is mixed with 10 % NaOH (100 mL) and refluxed overnight. The mixture is then extracted with ethyl acetate (50 mL x 3). The organic layers are combined and washed successively with 50 mL portions of 1 N HCl, sat. NaHCO₃, water, and brine. It is then dried over Na₂SO₄ and concentrated. The residue is chromatographed in silica gel using ethyl acetate as eluant to yield **10** as a yellowish oil (5.84 g, 30.6 mmol, 31 %). ¹H NMR (400 MHz, CDCl₃) δ 1.33-1.38 (m, 1 H), 1.63-1.77 (m, 3 H), 2.75-2.81 (m, 1 H), 2.87-2.91 (m, 1 H), 3.22-3.46 (m, 3 H), 4.43-4.50 (m, 2 H) 7.20-7.28 (m, 5 H); ¹³C NMR (100 MHz, CDCl₃) δ 24.7, 27.4, 33.6, 45.9, 57.4, 72.6, 73.3, 127.0, 127.1, 127.6, 127.8, 137.9.

Synthesis of (1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-carbamic acid *tert*-butyl ester (13)

To a solution of **10** (2.67 g, 14.0 mmol) and triethylamine (5 mL) in THF (10 mL) at r.t. is added a solution of **12** (4.40 g, 14.0 mmol) via cannula. After complete addition, the solution is stirred overnight. THF is removed *in vacuo* and the residue taken in ether. The ether solution is washed successively with 50 mL portions of 0.5 N HCl, sat. NaHCO₃, water, and brine. It is then dried over Na₂SO₄ and concentrated. The residue is chromatographed in silica gel using hexane/ethyl acetate (3:1:) as eluant to yield **13** as a colorless oil (4.75 g, 12.16 mmol, 87 %). %).

¹H NMR (400 MHz, CDCl₃) δ 0.88 (t, J= 6.7 Hz, 3 H), 0.94 (d, J= 6.7, 3 H), 1.43 (s, 9 H), 1.84-2.09 (m, 5 H), 2.00-2.10 (m, 1 H); 2.28-2.36 (m 1 H), 2.49 (dd, J= 16.7, 6.2 Hz, 1 H), 2.74 (dd, J= 16.7, 8.2, 1 H), 3.47-3.52 (m, 1 H), 3.55-3.60 (m, 2 H), 3.62-3.68 (m, 2 H), 4.25-4.29 (m, 1 H), 4.32-4.35 (m, 1 H), 4.48-4.52 (m, 2 H), 5.26-5.31 (m, 1 H), 7.25-7.36 (m, 5 H); ¹³C NMR (100 MHz, CDCl₃) δ 17.8, 19.8, 24.8, 27.6, 28.7, 31.9, 48.0, 57.0, 57.3, 70.4, 73.5, 79.7, 127.3, 127.5,

128.2, 138.9, 157.1, 172.5. HRMS calcd for $C_{22}H_{34}N_2O_4$ (MH^+):
391.2596. Found (DCI): 391.2612 ($\Delta = -3.9$ ppm).

Synthesis of 2-amino-1-(2-benzyloxymethyl-pyrrolidin-1-yl)-3-

5 methyl-butan-1-one (14)

To a solution of **13** (4.75 g, 12.16 mmol) in CH_2Cl_2 (10 mL) is added TFA (10 mL). The solution is stirred for 1 h and then quenched with a saturated solution of $NaHCO_3$ (50 mL). The mixture is extracted with CH_2Cl_2 (50 mL x 2). The combined organic layers
10 are washed with 50 mL portions of sat. $NaHCO_3$, water, and brine. It is then dried over Na_2SO_4 and concentrated to give pure **14** as a yellow oil (3.07 g, 10.56 mmol, 87%). 1H NMR (400 MHz, $CDCl_3$) δ 0.87 (t, $J = 6.8$ Hz, 3 H), 0.91 (d, $J = 6.8$, 3 H), 1.65-1.79 (m, 2 H), 1.79-1.96 (m, 2 H), 1.99-2.17 (m, 1 H); 3.27-3.45 (m 1 H), 3.46-3.54
15 (m, 1 H), 3.59-3.62 (m, 1 H), 4.33-4.38 (m, 1 H), 4.46-4.54 (m, 2 H), 7.27-7.42 (m, 5 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 16.9, 19.8, 24.4, 27.2, 47.2, 56.6, 58.3, 70.1, 73.1, 127.3, 127.4, 128.2, 138.4, 173.8. HRMS calcd for $C_{17}H_{27}N_2O_2$ (MH^+): 291.2072. Found (DCI): 291.2088 ($\Delta = -5.3$ ppm).

(

Synthesis of 3-(R)-(1-(2-(S)-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-(S)-methyl-propylcarbamoyl)-octanoic acid tert-butyl ester (15)

To solution of **14** (3.06 g, 10.56 mmol), triethylamine (5 mL), and THF (100 mL) is added a solution of **8** in THF (40 mL). The solution is stirred overnight and then washed with 50 mL portions of 1 N HCl, sat. NaHCO₃, water, and brine. It is then dried over Na₂SO₄ and concentrated *in vacuo*. The residue is chromatographed in silica gel using hexane/ethyl acetate (3:1) as eluant to give **15** as a clear colorless oil (5.25 g, 10.17 mmol, 96%). ¹H NMR (400 MHz, CDCl₃) δ 0.85 (t, J= 6.3 Hz, 3 H), 0.92 (d, J= 13.1, 3 H), 0.94 (d, J= 13.1, 3 H), 1.09-1.34 (m, 6 H), 1.43 (s, 9 H), 1.58-1.66 (m, 2 H), 1.68-1.76 (m, 2 H), 1.85-1.97 (m, 4 H), 2.00-2.10 (m, 1 H); 2.28-2.36 (m, 1 H), 2.49 (dd, J= 16.7, 6.2 Hz, 1 H), 2.74 (dd, J= 16.7, 8.2, 1 H), 3.10-3.21 (m, 2 H), 3.46-3.52 (m, 2 H), 3.67-3.77 (m, 2 H), 4.28-4.33 (m, 2 H), 4.49 (s, 2 H), 4.59-4.63 (m, 2 H), 7.29-7.37 (m, 5 H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 17.4, 19.0, 22.3, 24.3, 25.3, 27.2, 27.9, 31.5, 32.2, 34.8, 37.8, 42.9, 47.5, 55.3, 56.5, 69.9, 73.0, 80.3, 127.3, 127.4,

128.2, 170.3, 171.5, 174.4. HRMS calcd for C₃₀H₄₉N₂O₅ (MH⁺):
517.3641. Found (DCI): 517.3613 (Δ = 5.5 ppm).

Synthesis of 3-(*R*)-(1-(2-(*S*)-benzyloxymethyl-pyrrolidine-1-
5 carbonyl)-2-(*S*)-methyl-propylcarbamoyl)-octanoic acid (16)

To a solution of 15 (5.16 g, 10.0 mmol) in CH₂Cl₂ (10 mL)
is added TFA (10 mL). The solution is stirred for 2 h and then
diluted with CH₂Cl₂ (50 mL). The solution is washed with 50 mL
portions of 1 N HCl, water, and brine. It is then dried over Na₂SO₄
10 and concentrated to give pure 16 as a clear colorless oil (4.19 g, 9.10
mmol, 91%). ¹H NMR (400 MHz, CDCl₃) δ 0.84 (t, *J* = 6.8 Hz, 3 H),
0.91 (d, *J* = 13.1, 3 H), 0.93 (d, *J* = 13.1, 3 H), 1.14-1.29 (m, 6 H), 1.30-
1.37 (m, 2 H), 1.39-1.46 (m, 2 H), 1.91-2.15 (m, 4 H), 3.08-3.18 (m, 1
H), 3.56-3.59 (m, 2 H), 3.45 (dd, *J* = 16.8, 6.1 Hz, 1 H), 3.78 (dd, *J* =
15 16.8, 8.1, 1 H), 3.89-3.92 (m, 1 H); 4.26-4.37 (m, 1 H), 4.48 (s, 2
H), 4.57 (t, *J* = 8.7 Hz, 1 H), 7.28-7.40 (m, 5 H); ¹³C NMR (100 MHz,
CDCl₃) δ 13.7, 18.2, 18.7, 22.3, 24.2, 26.3, 26.6, 30.9, 31.3, 32.2,
34.1, 36.1, 40.9, 42.2, 48.8, 57.0, 58.1, 69.5, 73.7, 127.4, 127.6,

((

128.3, 137.2, 171.5, 176.1, 176.8. HRMS calcd for C₂₆H₄₀N₂O₅ (MH⁺): 461.3015. Found (DCI): 461.3023 (Δ = -1.6 ppm).

Synthesis of 3-(R)-(1-(2-(S)-benzyloxymethyl-pyrrolidine-1-
5 carbonyl)-2-(S)-methyl-propylcarbamoyl)-octanoic acid 2,5-dioxo-
pyrrolidin-1-yl ester (17)

To a solution of **16** (4.19 g, 9.10 mmol) and *N*-hydroxysuccinimide (1.88 g, 16.38 mmol) in 1,4-dioxane (30 mL) is added a solution of DCC (2.472 g, 12 mmol) in 12 mL dioxane. The
10 mixture is stirred overnight and filtered thru celite. The solids are washed with cold acetone and the filtrate concentrated *in vacuo*. The residue is redissolved in acetone, cooled to 0°C, and filtered. The filtrate is concentrated and the residue taken in ether. The solution is washed with 50 mL portions of 0.5 N HCl, sat. NaHCO₃,
15 water, and brine. It is then dried over Na₂SO₄ and concentrated. The residue is chromatographed in silica gel using hexane/ethyl acetate (1:10) as eluant to yield **17** as a white solid (4.313 g, 7.73 mmol, 85 %). ¹H NMR (400 MHz, CDCl₃) δ 0.84 (t, J= 6.7 Hz, 3 H), 0.91 (d, J= 13.1, 3 H), 0.93 (d, J= 13.1, 3 H), 1.05-1.16 (m, 2 H), 1.21-1.30 (m, 2

H), 1.57-1.62 (m, 2 H), 1.64-1.72 (m, 2 H), 1.87-2.10 (m, 4 H), 2.43-2.51 (m, 1 H), 2.67-2.79 (m, 2 H), 3.45-3.50 (m, 2 H), 3.55 (dd, J= 9.2, 2.8, 1 Hz, 1 H), 3.63 (dd, J= 9.2, 5.6 Hz, 1 H), 4.30 (bs, 4 H), 4.48 (s, 2 H); 4.60 (t, J= 8.5 Hz, 2 H), 7.27-7.35 (m, 5 H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.8, 17.7, 19.2, 22.3, 25.5, 26.5, 26.8, 31.2, 32.4, 33.5, 36.7, 42.7, 47.8, 55.7, 56.8, 69.7, 73.1, 127.3, 127.5, 128.3, 138.2, 167.4, 170.7, 173.2, 175.0, 175.3. HRMS calcd for $\text{C}_{30}\text{H}_{44}\text{N}_3\text{O}_7$ (MH^+): 558.3179. Found (FAB): 558.3184 ($\Delta = 0.5$ ppm).

10

Synthesis of *N*4-benzyloxy-*N*1-(1-(2-(*S*)-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-(*S*)-methyl-propyl)-2-(*R*)-pentylsuccinamide (19)

15 A solution of 17 (2.50 g, 4.49 mmol) in DMF (20 mL) is added, via cannula, to a suspension of 18 (1.12 g, 7.0 mmol) in triethylamine (10 mL) and DMF (20 mL). The mixture is stirred overnight after which it is diluted with CH_2Cl_2 (50 mL) and washed with water (50 mL x 2), 1 N HCl (50 mL), sat. NaHCO_3 (50 mL), water

((

(50 mL), and brine (50 mL). The solution is dried over Na₂SO₄ and concentrated *in vacuo*. The residue is chromatographed in silica gel using hexane/ethyl acetate (1:10) as eluant to give **19** as a white solid (2.50 g, 4.42 mmol, 98 % yield). ¹H NMR (400 MHz, CDCl₃) δ

5 0.83 (t, J= 6.7 Hz, 3 H), 0.90 (d, J= 13.1, 3 H), 0.93 (d, J= 13.1, 3 H), 1.05-1.16 (m, 2 H), 1.21-1.30 (m, 2 H), 1.57-1.62 (m, 2 H), 1.64-1.72 (m, 2 H), 1.87-2.10 (m, 4 H), 2.43-2.51 (m 1 H), 2.67-2.79 (m, 2 H), 3.45-3.50 (m, 2 H), 3.55 (dd, J= 9.2, 2.8, 1 Hz, 1 H), 3.63 (dd, J= 9.2, 5.6 Hz, 1 H), 4.48 (s, 2 H); 4.60 (t, J= 8.5 Hz, 2 H), 4.87 (s, 2 H), 7.27-

10 7.37 (m, 10 H); ¹³C NMR (100 MHz, CDCl₃) δ 13.7, 18.2, 18.7, 22.3, 24.2, 26.3, 26.6, 30.9, 31.3, 32.2, 34.1, 36.1, 40.9, 42.2, 48.8, 57.0, 58.1, 69.5, 69.5, 73.7, 127.3, 127.5, 127.6, 128.3, 128.4, 128.5, 128.8 138.2, 171.9, 176.3, 177.2. HRMS calcd for C₃₃H₄₈N₃O₅ (MH⁺): 566.3593. Found (FAB): 566.3573 (Δ = -2.1 ppm).

15

Synthesis of (S,S,R)-actinonin (1)

Pd(OH)₂/C (Pearlman's catalyst) (525 g, ~ 100 mg Pd content) in a 100 mL two-neck round bottom flask fitted with a stirring bar is activated by repeated evacuation of the flask and


introduction of hydrogen gas. Once activated, a solution of 19 (2.50 g, 4.42 mmol) in methanol (50 mL) is added via syringe. The amount of hydrogen consumed is measured and the reaction is monitored closely by TLC. Once the amount of calculated hydrogen gas is exceeded and the starting material totally consumed, the hydrogen is removed and the reaction mixture filtered through celite. The solids are washed with liberal amounts of methanol. The methanol is removed *in vacuo* and the residue chromatographed in silica gel using CH₂Cl₂/CH₃OH (10:1) as eluant to afford 1 as an off-white solid (3.757 g, 9.74 mmol, 82 %). (α)²¹_D -51 (c=0.19, CH₃OH); m.p. 141.5-142.0 °C, mixed m.p. 141.7-142.4 °C, (m.p. of commercial sample (Sigma®) 140.6-141.4 °C) (lit.² 148-149 °C). ¹H NMR (400 MHz, CDCl₃) δ 0.71 (t, J= 6.6 Hz, 3 H), 0.95-1.18 (m, 11 H), 1.25-1.46 (m, 2 H), 1.50-1.61 (m, 1 H), 1.51-1.72 (m, 1 H), 1.76-1.95 (m, 2 H), 1.96-2.06 (m, 1 H), 2.22-2.34 (m, 1 H), 2.68 (dd, J= 13.8, 5.6 Hz, 1 H), 3.04 (dd, J= 13.8, 7.5 Hz, 1 H), 3.51-3.62 (m, 2 H), 3.82-3.91 (m, 1 H), 4.08-4.18 (m, 2 H), 4.52-4.60 (m, 1 H), 4.95 (t, J=8.4 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 16.3, 21.1, 21.9, 24.1, 24.9, 26.7, 29.5,

29.9, 33.6, 34.1, 35.5, 39.5, 45.6, 50.3, 59.3, 62.4, 65.5, 171.3, 174.4, 177.8. m/z 386.3 (MH^+).

5

EXAMPLE 5

Synthesis of Analogs of (*S,S,R*)-actinonin
*N*4-hydroxy-*N*1-(1-(2-methyl-pyrrolidine-1-carbonyl)-3-methyl-propyl)-2-pentyl-
succinamide (27)




10

The synthesis is comprised of the following steps: (a) a solution of 2-(*S*)- methylpyrrolidine hydrobromide **20** in dimethylformamide is treated with triethylamine followed by a solution of 2-*tert*-butoxycarbonylamino-3-methylbutyric acid 2,5-dioxo-pyrrolidin-1-yl **12** in dimethylformamide to yield (1-(2-methylpyrrolidine-1-carbonyl)-2-methyl-propyl)-carbamic acid *tert*-butyl ester **21**; which is then (b) dissolved in methylene chloride, or any suitable solvent, and treated with trifluoroacetic acid to yield 2-

(
(
amino-1-(2-methylpyrrolidin-1-yl)-3-methylbutan-1-one 22; (c) a
solution of 22 in dimethylformamide is treated with triethylamine
followed by a solution of 8 in dimethylformamide to yield 3-(1-(2-
(S)- methylpyrrolidine-1-carbonyl)-2-(S)-methylpropyl-carbamoyl)-
5 octanoic acid *tert*-butyl ester 23; (d) treatment of 23 in
dichloromethane with trifluoroacetic acid to yield 3-(1-(2-methyl-
pyrrolidine-1-carbonyl)-2-methyl-propylcarbamoyl)-octanoic acid
24; (e) treatment of a solution 24 and hydroxysuccinamide 7 with
dicyclohexylcarbodiimide to afford 3-(1-(2-methyl-pyrrolidine-1-
10 carbonyl)-2-methylpropylcarbamoyl)-octanoic acid 2,5-dioxo-
pyrrolidin-1-yl ester 25; (f) treatment of a suspension of *O*-
benzylhydroxyamine hydrochloride 18 in dimethylformamide with
triethylamine followed by a solution of 25 in dimethylformamide to
afford *N*4-benzyloxy-*N*1-(1-(2-benzyloxymethyl-pyrrolidine-1-
15 carbonyl)-2-methyl-propyl)-2-pentyl-succinamide 26. (g)
hydrogenating 26 with hydrogen gas and palladium in activated
carbon wherein *N*4-hydroxy-*N*1-(1-(2-methyl-pyrrolidine-1-
carbonyl)-3-methyl-propyl)-2-pentyl-succinamide 27 is thereby
formed.

N4-hydroxy-N1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl-succinamide (35)



The synthesis is comprised of the following steps: (a) a solution of 2-(*S*)-benzyloxymethylpyrrolidine **10** in THF is treated with triethylamine followed by a solution of 2-*tert*-butoxy carbonyl amino-4-methylpentanoic acid 2,5-dioxo-pyrrolidin-1-yl **28** in THF to yield (1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-3-methyl-isobutyl)-carbamic acid *tert*-butyl ester **29**; which is then (b) dissolved in methylene chloride and treated with trifluoroacetic acid to yield 2-amino-1-(2-benzyloxymethylpyrrolidin-1-yl)-4-methylpentan-1-one **30**; (c) a solution of **30** in dimethylformide or any suitable solvent is treated with triethylamine followed by a solution of **8** in dimethylformamide or any suitable solvent to yield 3-(1-(2-(*S*)-benzyloxymethylpyrrolidine-1-carbonyl)-2-(*S*)-methyl isopropyl -carbamoyl)-octanoic acid *tert*-butyl ester **31**; (d) treatment of **31** in dichloromethane with trifluoroacetic acid to yield

3-(1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methyl-isobutyl
carbamoyl)-octanoic acid **32**; (e) treatment of a solution **32** and
hydroxysuccinamide with dicyclohexylcarbodiimide or any suitable
imide to afford 3-(1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-
5 methylisocarbamoyl)-octanoic acid 2,5-dioxo-pyrrolidin-1-yl ester
33; (f) treatment of a suspension of *O*-benzylhydroxyamine
hydrochloride **18** in dimethylformamide with triethylamine followed
by a solution of **33** in dimethylformamide to afford *N*4-benzyloxy-
*N*1-(1-(2-benzyloxymethyl-pyrrolidine-1-carbonyl)-2-methyl-
10 isobutyl) -2-pentyl-succinamide **34**. (g) hydrogenating **34** with
hydrogen gas and palladium hydroxide in activated carbon wherein
*N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-
methyl-butyl)-2-pentyl-succinamide **35** is thereby formed.


15

EXAMPLE 6

Structure and nomenclature of additional analogs of (S,S,R)-
actinonin


N4-hydroxy-N1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl succinamide (41)

5




N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-N4-hydroxy-2-pentyl-succinamide (42)

10




N4-hydroxy-N1-(1-(4-hydroxy-benzyl)-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide (43)

15




*N*4-hydroxy-*N*1-(2-(2-hydroxymethyl-pyrrolidin-1-yl)-1(1*H*-indol-3-yl-methyl)-2-oxo-ethyl)-2-pentyl-succinamide (44)

5




*N*1-(5-amino-1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-pentyl)-*N*4-hydroxy-2-pentyl-succinamide (45)

10




*N*4-hydroxy-*N*1-(1-(2-hydroxymethyl-piperidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (46)

15




N4-hydroxy-N1-(1-(2-hydroxycarbamoyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl succinamide (47)

5




N4-hydroxy-N1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-methyl-succinamide (48)

10




N1-(1-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-3-methyl-butyl)-2-pentyl-succinamide (49)


15




N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide (50).



N1-(1-(2-methyl-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (51)




N4-hydroxy-N1-(1-benzyl-2-(2-methyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide (52)




N4-hydroxy-N1-(1-(2-methylamine-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (53)

5




3-[1-(2-hydroxymethyl-pyrrolidin-1-yl)-2-benzylcarbamoyl]-octanoic acid (54)

10




N4-hydroxy-N1-(1-(methyl-2-carboxy-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (55)

15




N4-hydroxy-N1-(1-(2-carboxy-pyrrolidine-1-carbonyl)-2-methyl-propyl)-2-pentyl-succinamide (56)

5




N4, N4-diethyl-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide (57)

10




N4-ethyl-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl)-2-pentyl-succinamide (58)

15




N4-(2,4-methoxybenzyl)-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (59)

5




2-(N',N'-dimethyl-hydrazinocarbonylmethyl)-heptanoic acid [1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-amide (60)

10




N4-(4-nitrobenzyl)-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (61)

15




2-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-heptanoic acid [1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-amide (62)

5




N4-(methoxy)-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (63)

10




N4-(piperidin-1-carbonyl)-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (64)

15



((

N4, N4-methoxymethyl-N1-(1-benzyl-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl -2-pentyl-succinamide (65)



EXAMPLE 7

10

Cytotoxicity and anti-tumor activity of actinonin

The therapeutic use of the compounds of the present invention in treatment of neoplastic diseases is illustrated. Actinonin was assayed for cytotoxicity in human ovarian carcinoma, prostate carcinoma, mammary carcinoma, head and neck squamous cell carcinoma (HNSSC), non-small-cell-lung-cancer adenocarcinoma (NSCLC-AdCa), and non-small-cell-lung-cancer squamous cells (NSCLC-SSC) (15). Actinonin was also tested against acute myleogenous leukemia (AML) cells. The results are shown in Table 2.

20 Actinonin is remarkably cytotoxic in the μM range against all the cell

lines tested. These growth inhibitory properties provide for the use of these compounds as anti-tumor agents or for the use in the treatment of neoplastic diseases.

5

TABLE 2

Summary of cell culture data with actinonin^a

Cell line	Histology	IC ₅₀ (μM ± SEM)	n Value
A2780	Ovarian Ca	4.8±1	3
TSU-PR ¹	Prostate Ca	9.1±1.5	3
PC-3	Prostate Ca	10.0±1	3
DU-145	Prostate Ca	17.03	3
HL-60	PML (CML?)	6.8±1	4
MDA-MB468	Mammary Ca	7.1±1	4
SK-BRIII	Mammary Ca	7.9±1	3
HT1080	HNSSC	11.0±2	4
SK-LC-8	NSCLC-AdCa	14.0±2	3
SK-LC-16	NSCLC-SSC	12.0±2	3

^aCells were grown for 5 days ± varying concentrations of actinonin. Cell number were determined by XTT assay on an automatic plate reader.

10

Actinonin was also evaluated against the CWR22 human prostate tumor xenografted in nude mice (15). The results are summarized in Table 3. Actinonin shows excellent tumor growth inhibition at a dose slightly below the maximum tolerated dose (MTD) for the mouse.

TABLE 3

Anti-tumor activity of actinonin against the CWR22 human prostate tumor in nude mice.^a

R _x (mg/kg)	Change in weight (%)	Ave. Tumor Diameter (mm±SEM)	Change in tumor Vol. (mm ³)	Inhibition T/C %
---		13.3 ±2	+1190	
300 ip	-2	5.4±1	+36	97
600 ip	-3	7.1±2	+142	88

^aInitial tumor diameter = 4.4 + 0.3 mm (45 mm³)

EXAMPLE 8

Evaluation of actinonin and its analogs against Daudi lymphomic and HL-60 leukemic cells

5 Actinonin was purchased from Sigma (St. Louis, MO). Biotinylated-Actinonin and all analogs were synthesized. Actinonin stock solution was 5 mg/ml in 10% ethanol. Biotinylated-actinonin and all other analogs were diluted in 10% DMSO to give stock solutions in the range of 1-20 mg/ml.

10

Cell Lines and culture conditions

Daudi (B lineage Burkitt's lymphoma, CD13 negative) and HL60 (acute myeloid leukemia, CD13 positive) cells were maintained in culture using RPMI 1640 supplemented with 10% heat-inactivated
15 FBS (Omega Scientific, Inc., Tarzana, CA) and 1% L-glutamine (Gibco/Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere of 5% CO₂. Cell viability was higher than 90%, and cells were free of mycoplasma contamination.

Inhibition of tritiated thymidine incorporation.

An aliquot of 200 ul of cells (10,000 cells/well) was washed and incubated at 37°C in 96-well plates in the presence or absence of actinonin/analog. Serial dilutions were made in 5 complete media. After 5 days of incubation, 50 ul of 10 uCi/mL tritiated thymidine (PerkinElmer, Boston, MA) was added to each well and allowed to incorporate for 5 hours. Plates were frozen at -80°C overnight and cells were harvested onto filtermats (Wallac, Finland) using a semi-automatic harvester (Skatron, Sterling, VA). 10 Filtermats were counted in a 1205 Betaplate™ liquid scintillation counter (Wallac, Finland). Tables 4 and 5 show the results of the actinonin analogs on cell viability. The reference numbers refer to those analogs disclosed in Example 6. Compounds 35, 42, 48, 52, 53, and 56 are effective at inhibiting cell growth.

15

20

TABLE 4

	5 day thymidine incorporation	
Compound	Daudi	HL60
	IC50 (u g /mL)	IC50 (u g /mL)
Actinonin	2.6	4.1
Biotin- Actinonin	>100	>100
#35	5.7	7.1
#49	>50	>50
#51	6.6	6.9
#42	5.8	7.1
#48	8.0	10.5
#52	1.2	5.2
#53	7.0	10.0
Biotin-Act	20.0	50.0
#54	ND	>100
#57	ND	>100
#58	ND	>100
#59	ND	>100
#60	ND	90.0
#61	ND	>100
#62	ND	>100
#63	ND	>100
#64	ND	>100
#65	ND	>100
Calpeptin	6.0	50.0
DL-Thiorphan	>100	>100
#55	0.4016	2.773
#56	>100	>100

TABLE 5

Compound	5 day thymidine incorporation	
	Daudi	HL60
	IC50 (uM)	IC50 (uM)
Actinonin	6.7	10.6
Biotin-Actinonin	>138	>138
#35	14.1	17.7
#49	>130	>130
#51	18.7	19.5
#42	12.9	15.8
#48	22.4	29.5
#52	2.7	12.1
#53	18.2	26.0
Biotin-Act	27.6	69.1
#54	ND	>239
#57	ND	>211
#58	ND	>225
#59	ND	>176
#60	ND	195.5
#61	ND	>181
#62	ND	>200
#63	ND	>224
#64	ND	>206
#65	ND	>217
Calpeptin	16.6	137.9
DL-Thiorphan	>395	>395
#55	0.97	6.7
#56	>251	>251

Corrected concentrations for cuvette dilution (1/50) in PDF assay

((

The following references are cited herein:

1. Gordon, et al., *Nature*, Vol. 195, pg. 701 (1962).
2. Tieku, et al., *Biological Pharmacology* 1992, 44, 1725.
3. Fujii, et al., *Biol. Pharm. Bull.*, 1996, 19, 6.
- 5 4. Xu, Y., Lai, L.T., Gabrilove, J. L., Scheinberg, D. A. *Clinical Cancer Research*, 1998, 4, 171.
5. Sayama, et al., *Cancer Letters*, 1995, 171.
6. Bouboutou, R., Lelievre, Y., Boiziau, J., Cartwright, T. in *Second Forum on Peptides*, Eds. A. Aubry, M. Marraud, B. Vitoux. Colloque
- 10 INSERM: John Libbey Eurotext Ltd., 1989, 174, 341.
7. Harper, E. *Ann. Rev. Biochem*, 1980, 49, 1063.
8. Gordon, et al., *J. Chem. Soc. Perkin Trans 1*. 1975, 819-824.
9. Umezawa, et al., *J. Antibiotics*, 1985, 38, 1629-1630.
10. Faucher, et al., *J. Antibiotics*, 1987, 40, 1757-1761.
- 15 11. Anderson, et al., *J. Chem. Soc. Perkin Trans 1*. 1975, 825-830.
12. Bashiardes, G., Bodwell, G. J., Davies, S.G. *J. Chem. Soc. Perkin Trans. 1*, 1993, 459-469.
13. Evans, et al., *J. Am. Chem. Soc.* 1982, 104, 1737.
14. Gage, J.R., Evans, D.A. *Org, Synth*. 1989, 68, 83.

15. Sirotnak, F. M., DeGraw, J. I., Colwell, W. T., Piper, J. R. *Cancer Chemother. Pharmacol* 1998, 42, 313.
16. Broek, L. A. G. M. van den, Porskamp, P. A.T. W., Haltiwanger, R. C., Zwanenburg, B. *J. Org. Chem.*, 1984, 49, 1691-1695.
- 5 17. Giglione, C., Serero, A., Pierre, M., Boisson, B., and Meinnel, T. *The EMBO Journal* 2000, 19(21):5916-29.
18. Dirk, L.M.A., Williams, M.A., and Houtz, R.L. *Plant Physiology*, 2001, 127:97-107.
19. Bracchi-Ricard, V., Nguyen, K.T., Zhou, Y., Ravi Rajagopalan, P.T., Chakrabarti, D., and Pei, D. *Archives of Biochemistry and Biophysics*, 2001, 396(2):162-170.
- 10

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was indicated to be incorporated specifically and individually by reference.

15

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain

20

the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary,
5 and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.